Olaparib Clinical Trials (65 Recruiting)

Showing 1–20 of 66 trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more

National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377

Recruiting

Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more

National Cancer Institute (NCI)152 enrolled453 locationsNCT04858334

Recruiting

Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more

National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328

Recruiting

Phase 1

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA MutationBRCA1 MutationBRCA2 Mutation+3 more

Varun Monga, MBBS18 enrolled1 locationNCT06177171

Recruiting

Phase 1Phase 2

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Prostatic Neoplasms, Castration-Resistant

Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386

Recruiting

Phase 1Phase 2

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors

National Cancer Institute (NCI)56 enrolled1 locationNCT04086485

Recruiting

Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms

Merck Sharp & Dohme LLC2,400 enrolled291 locationsNCT06966700

Recruiting

Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies

Merck Sharp & Dohme LLC3,500 enrolled781 locationsNCT03486873

Recruiting

Phase 1

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma

National Cancer Institute (NCI)42 enrolled27 locationsNCT04633239

Recruiting

Phase 1

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmPlatinum-Resistant Ovarian High Grade Serous Adenocarcinoma

National Cancer Institute (NCI)55 enrolled7 locationsNCT04585958

Recruiting

Phase 2

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Breast CancerBreast Neoplasms

Merck Sharp & Dohme LLC372 enrolled17 locationsNCT06797635

Recruiting

Phase 2

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Gynecologic CancersFallopian Tube CancerPlatinum-sensitive Ovarian Cancer+1 more

AbbVie377 enrolled14 locationsNCT07024784

Recruiting

Phase 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin

American Society of Clinical Oncology4,200 enrolled174 locationsNCT02693535

Recruiting

Phase 1

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Locally Advanced Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8+1 more

National Cancer Institute (NCI)18 enrolled11 locationsNCT05411094

Recruiting

Phase 2Phase 3

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

Endometrial Cancer

Leiden University Medical Center1,615 enrolled14 locationsNCT05255653

Recruiting

Phase 2

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Cholangiocarcinoma

Australasian Gastro-Intestinal Trials Group40 enrolled8 locationsNCT06441747

Recruiting

Phase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more

Imunon500 enrolled7 locationsNCT06915025

Recruiting

Phase 1Phase 2

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung CancerExtensive-stage Small-cell Lung Cancer

Sichuan University45 enrolled1 locationNCT06217757

Recruiting

Phase 1Phase 2

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Advanced Solid TumorMetastatic Solid Tumor

Artios Pharma Ltd181 enrolled12 locationsNCT05898399

Recruiting

Phase 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more

Rahul Aggarwal89 enrolled3 locationsNCT03682289